Results 121 to 130 of about 73,182 (252)

SLAMF6 Enhances the Efficacy of Anti‐PD‐L1 Immunotherapy in CRC Through the STAT1/CXCL10 Signaling Axis

open access: yesCancer Science, EarlyView.
SLAMF6 recruits SHP‐2 to activate STAT1, upregulates CXCL10 and PD‐L1, promotes CD8+T cell infiltration, and enhances the efficacy of anti‐PD‐L1 therapy. ABSTRACT As a T‐cell receptor co‐stimulatory protein, signaling lymphocyte activation molecule family 6 (SLAMF6) is a member of the immune cell activating receptor family and is expressed on T cells ...
Yu Wu   +8 more
wiley   +1 more source

Treatment‐Free Remission in Chronic Myeloid Leukemia: Toward Precision and Personalized Approaches to Functional Cure

open access: yesCancer Science, EarlyView.
Immune surveillance of residual leukemic stem cells after tyrosine kinase inhibitor discontinuation involves coordinated NK‐cell, CTL, Treg, pDC, and neutrophil activity that predicts treatment‐free remission, while exhausted CTLs and Treg expansion predict relapse in chronic myeloid leukemia.
Hiroshi Ureshino, Shinya Kimura
wiley   +1 more source

Immune checkpoints: cross-disease insights and clinical dilemmas. [PDF]

open access: yesBiomark Res
Shu Y   +7 more
europepmc   +1 more source

Advances in Radiotherapy for Neoadjuvant Therapy of Stage III Non‐Small Cell Lung Cancer

open access: yesCancer Science, EarlyView.
This review summarizes three neoadjuvant radiotherapy techniques for stage III NSCLC, highlighting SFRT's low‐toxicity dual immune‐tumor control benefits and radioimmunotherapy's superior pathological response to guide precise multimodal treatment. ABSTRACT This review aims to systematically summarize the mechanisms of action, clinical evolution, and ...
Qinrong Mao   +5 more
wiley   +1 more source

A20 Inhibits IFN‐γ Signaling in Hepatocellular Carcinoma Cells by Binding to STAT1, Compromising Anti‐Tumor Immunity

open access: yesCancer Science, EarlyView.
A20 suppresses IFN‐γ signaling in HCC cells by binding to STAT1 through its ZnF7 domain, thereby reducing CXCL9, CXCL10, and HLA‐ABC expression, ultimately impairing CD8+ T‐cell‐mediated anti‐tumor immunity. ABSTRACT Immune checkpoint blockade (ICB) has demonstrated efficacy in clinical cancer therapy; however, a significant proportion of cancer ...
Yanlei Dong   +14 more
wiley   +1 more source

Advances in the Role of Chemokines in Microwave Ablation‐Based Combinatorial Immunotherapy

open access: yesCancer Science, EarlyView.
MWA can initiate antitumor immunity through tumor antigen release and innate immune activation, but iMWA may instead promote an immunosuppressive microenvironment. Combining MWA with immunotherapeutic strategies offers a promising approach to enhance systemic immunity and suppress residual and distant tumors.
Ruijie An, Ningning He, Wendong Gu
wiley   +1 more source

Single‐Cell and Spatial Analysis Reveal the Differences Between Left‐Sided and Right‐Sided Colorectal Cancer

open access: yesCell Proliferation, EarlyView.
Single‐cell and spatial analysis revealed distinct CRC microenvironments by tumour laterality. Right‐sided tumours showed enhanced germinal centre B cells, CXCL13+ T cells, and organized TLS‐immune crosstalk via CCL19/21‐CCR7, suggesting better immunotherapy response.
Zongnai Zhang   +8 more
wiley   +1 more source

Viruses in the tumor immune microenvironment: implications for immunotherapy. [PDF]

open access: yesFront Immunol
Chen X   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy